Investor Watch Series | Funding – Who to Watch | S2 E2

InvestorWatch Series

Welcome To Investor Watch

In this series will be going over trials, research and other clinical verticals that receive funding. Below are the ones we cover in this episode:

  • Amylyx Pharmaceuticals Raises $30 Million in Series B Funding to Continue Development of AMX0035 in ALS and Alzheimer’s Disease Amylyx Pharmaceuticals announced it has closed an oversubscribed $30 million Series B financing, led by Morningside Ventures, with participation from other investors. Amylyx has closed more than $45M in financing in 2020. Proceeds will enable continued investment in the company’s lead product candidate AMX0035 in ALS and Alzheimer’s disease. AMX0035 is a first-in-class investigational therapy designed to reduce neuronal death and dysfunction. AMX0035 targets mitochondrial and endoplasmic reticulum-dependent neuronal degeneration pathways. The U.S FDA and the European Medicines Agency (EMA) have designated AMX0035 as an Orphan Drug 
  • NASDAQ the Place to be as Euro Biotech Seek Access to Vast Pools of Investor Dollars: Large pools of capital are flowing into biotech funds and companies as a flurry of European biotech seek access to New York’s Nasdaq in a frantic race to get in on the action. With a COVID-19 rush for vaccines and therapies, the Nasdaq biotech index (NBI) peaks about 25% in the second calendar quarter, the best run in a couple decades hitting a valuation of $1.2 trillion. Bankers report UK and Euro midsized biotech are talking with New York investors about listings there. While investors in Spain want profits today, Nasdaq investors want large returns in the future. 
  • Germany’s COVID-19 Vaccine Maker BioNTech Secures $250m from Singapore State Investor Temasek: Temasek, Singapore’s state investor as well as a group of other investors will inject $250 million into BioNTech, (Nasdaq: BNTX) the Germany biotech company developing an MRNA-based COVID-19 vaccine with Pfizer. This latest investment is via private placement 
  • Bolt Biotherapeutics Completes $93.5 Million Series C Financing to Support BDC-1001 in HER2-Expressing Cancers: Bolt Biotherapeutics announced the closing of an oversubscribed $93.5 million Series C financing led by Sofinnova Investments. The Series C financing included participation from new investors RA Capital Management, Surveyor Capital (a Citadel Company), Rock Springs Capital, Samsara BioCapital and Pfizer Ventures as well as existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners and others. The funding from this round will be used to support the clinical development of the company’s lead Immune-Stimulating Antibody Conjugate (ISAC), BDC-1001, a systemically delivered monotherapy for HER2-expressing cancers. The financing will also support the expansion of the company’s pipeline of Boltbody therapeutics.